Search

Author/Creator Wu, Y-L

2. 322PThree-year overall survival update from the PACIFIC trial. (24th November 2019)

Authors:
Wu, Y-L; Gray, J E; Villegas, A; Daniel, D B; Vicente, D; Murakami, S; Hui, R; Kurata, T; Chiappori, A; Lee, K H; Cho, B C; Planchard, D; Paz-Ares, L; Faivre-Finn, C; Vansteenkiste, J F; Spigel, D R; Taboada, M; Dennis, P A; Özgüroğlu, M; Antonia, S J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 369OBiomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505). (25th November 2018)

Authors:
Zhou, Q; Zhang, X-C; Tu, H-Y; Gan, B; Wang, B-C; Xu, C-R; Chen, H-J; Zheng, M-Y; Wang, Z; Bai, X-Y; Sun, Y-L; Myers, A; Lv, X; Chakrabcorti, Y; Zhao, S; Yang, J-J; Wu, Y-L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 421PEGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). (22nd November 2017)

Authors:
Akamatsu, H; Delmonte, A; John, T; Su, W-C; Lee, J-S; Chang, G-C; Huang, X; Jenkins, S; Dearden, S; Wu, Y-L
Journal:
Annals of oncology
Issue:
Volume 28(2017)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). (24th November 2019)

Authors:
Wu, Y-L; Mok, T S K; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S-W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Papadimitrakopoulou, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 484PActivity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials. (24th November 2019)

Authors:
Gottfried, M; de Marinis, F; Tu, H; Laktionov, K K; Feng, J; Poltoratskiy, A; Zhao, J; Tan, E-H; Lee, V; Kowalski, D; Yang, C-T; Srinivasa, B; Passaro, A; Clementi, L; Tang, W; Huang, D C-L; Cseh, A; Park, K; Zhou, C; Wu, Y-L
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗